Optimized Design and Development of Ropinirole Loaded Nanoparticles for Restless Leg Syndrome

Restless Leg Syndrome (RLS) has a major impact on the quality of life and requires innovative approaches to improve symptom management. This study focuses on the design and development of Ropinirole-loaded nanoparticles for targeted intranasal delivery to enhance therapeutic outcomes in RLS patients.

Ropinirole, a dopamine agonist, was incorporated into chitosan nanoparticles with the help of the Box-Behnken design (BBD) to optimize key parameters such as particle size, polydispersity index (PDI), entrapment efficiency of the drug, and drug release kinetics. Characterization of the nanoparticles involved Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and other common techniques. Intranasal delivery was selected to circumvent the blood-brain barrier and deliver the drug across the nasal epithelial lining into the central nervous system.

The optimized nanoparticles had desirable physicochemical properties: sustained drug release, high entrapment efficiency, and thermal stability. These nanoparticles exhibited significant potential to reduce symptoms in RLS patients and minimize systemic side effects in the preclinical assessments.

The current study points to the potential of Ropinirole-loaded nanoparticles as a delivery system for treating RLS. Further clinical studies are warranted to confirm these results and establish both short- and long-term safety and efficacy.